Eagle Pharmaceuticals OverviewTrack Eagle Pharmaceuticals's EBIT ($30M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2023
Trailing 12 months ending Jun 30, 2023
As of the most recent data (June 2023), EGRX shows a EBIT of $30M. That compares with $58M in the prior-year period — down 47.6% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, EGRX's EBIT is now $30M (was $58M) — a 47.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Eagle Pharmaceuticals is outperforming or lagging.
The Healthcare sector average EBIT is about $22B. Eagle Pharmaceuticals is at $30M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how EGRX stacks up against individual peers as well.
Tracking EGRX's ebit over time shows whether Eagle Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $30M That compares with $58M in the prior-year period — down 47.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Eagle Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $30M) with ownership activity and broader fundamentals.
